Cancer testis antigens and NY-BR-1 expression in primary breast cancer: Prognostic and therapeutic implications

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Balafoutas, Dimitrios ^a   zur Hausen, Axel ^b   Mayer, Sebastian ^a   Hirschfeld, Marc ^a,c   Jaeger, Markus ^a   Denschlag, Dominik ^a   Gitsch, Gerald ^a   Jungbluth, Achim ^d   Stickeler, Elmar ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast Cancer; Cancer testis Antigen; Immunotherapy; NY BR 1; Prognosis

Indexed keywords

CANCER TESTIS ANTIGEN; DIFFERENTIATION ANTIGEN; GAGE ANTIGEN; MELANOMA ANTIGEN 1; NY BR 1 ANTIGEN; NY ESO 1 ANTIGEN; UNCLASSIFIED DRUG; BREAST CANCER ANTIGEN NY-BR-1, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; SURVIVAL TIME; TISSUE MICROARRAY; BIOSYNTHESIS; BREAST TUMOR; FEMALE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878345533     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-271     Document Type: Article

References (53)

1. Centers for Disease Control and Prevention: Breast Cancer Statistics http://www.cdc.gov/cancer/breast/statistics/, Centers for Disease Control and Prevention: Breast Cancer Statistics.
2. Stickeler E. Prognostic and predictive markers for treatment decisions in early breast cancer. Breast Care 2011, 6:193-198. 10.1159/000329471, 3132966, 21779224.
3. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647. 10.1126/science.1840703, 1840703.
4. Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA 2009, 106:13493-13498. 10.1073/pnas.0906840106, 2716388, 19651608.
5. Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, Stahl T, Cao Y, Zander AR, Bokemeyer C, Kroger N. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res 2009, 15:1343-1352. 10.1158/1078-0432.CCR-08-0989, 19190130.
6. Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H, Nishimura T. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 2006, 28:1089-1098.
7. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100:2014-2021. 10.1111/j.1349-7006.2009.01303.x, 19719775.
8. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998, 187:1349-1354. 10.1084/jem.187.8.1349, 2212223, 9547346.
9. Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK, Jager E. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and montanide ISA-51: association with survival. Int J Cancer 2010, 126:909-918.
10. Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. Clin Cancer Res 2009, 15:4467-4474. 10.1158/1078-0432.CCR-09-0582, 19531622.
11. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, et al. Vaccination with NY-ESO-1 protein and CpG in montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007, 104:8947-8952. 10.1073/pnas.0703395104, 1885608, 17517626.
12. Jager D, Filonenko V, Gout I, Frosina D, Eastlake-Wade S, Castelli S, Varga Z, Moch H, Chen YT, Busam KJ, et al. NY-BR-1 is a differentiation antigen of the mammary gland. Appl Immunohistochem Mol Morphol 2007, 15:77-83. 10.1097/01.pai.0000213111.05108.a0, 17536312.
13. Theurillat JP, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, Chen YT, Jager D, Knuth A, Moch H. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer 2007, 120:2411-2417. 10.1002/ijc.22376, 17294444.
14. Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E, Schormann C, de Bruijn D, Wadle A, Neumann F, et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 2006, 118:696-703. 10.1002/ijc.21352, 16094643.
15. Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004, 64:2199-2204. 10.1158/0008-5472.CAN-03-3070, 15026363.
16. Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, Neville AM, Nole F, Rotmensz N, Goldhirsch A. Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol 2011, 22:98-103. 10.1093/annonc/mdq325, 20610479.
17. Kruger S, Ola V, Feller AC, Fischer D, Friedrich M. Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility. Pathol Oncol Res 2007, 13:91-96. 10.1007/BF02893483, 17607369.
18. Jager D, Stockert E, Scanlan MJ, Gure AO, Jager E, Knuth A, Old LJ, Chen YT. Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res 1999, 59:6197-6204.
19. Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini JC. Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-a family. Int J Cancer 2000, 86:749-751. 10.1002/(SICI)1097-0215(20000601)86:5<749::AID-IJC24>3.0.CO;2-O, 10797302.
20. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, Willimann T, Harder F, Heberer M, Spagnoli GC. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995, 55:2236-2239.
21. Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Busam KJ, Old LJ. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 2000, 83:493-497. 10.1054/bjoc.2000.1291, 2374655, 10945497.
22. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001, 92:856-860. 10.1002/ijc.1282, 11351307.
23. Varga Z, Theurillat JP, Filonenko V, Sasse B, Odermatt B, Jungbluth AA, Chen YT, Old LJ, Knuth A, Jager D, Moch H. Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. Clin Cancer Res 2006, 12:2745-2751. 10.1158/1078-0432.CCR-05-2192, 16675566.
24. van Diest PJ, van Dam P, Henzen-Logmans SC, Berns E, van der Burg ME, Green J, Vergote I. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European organization for research and treatment of cancer-gynaecological cancer cooperative group. J Clin Pathol 1997, 50:801-804. 10.1136/jcp.50.10.801, 500257, 9462258.
25. Perez D, Herrmann T, Jungbluth AA, Samartzis P, Spagnoli G, Demartines N, Clavien PA, Marino S, Seifert B, Jaeger D. Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence. Int J Cancer 2008, 123:1551-1555. 10.1002/ijc.23698, 18646188.
26. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, O'Neill D, Zavilevich K, Albukh T, Christos P, Mazumdar M, et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors. Cancer Immun 2007, 7:11. 2935749, 17625806.
27. Tammela J, Jungbluth AA, Qian F, Santiago D, Scanlan MJ, Keitz B, Driscoll D, Rodabaugh K, Lele S, Old LJ, Odunsi K. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immun 2004, 4:10.
28. Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O, Neville AM. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 2011, 6:e17876. 10.1371/journal.pone.0017876, 3060908, 21437249.
29. Ries J, Mollaoglu N, Vairaktaris E, Neukam FW, Nkenke E. Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma. Anticancer Res 2009, 29:5125-5130.
30. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, Chauffaille ML, Andriolo A, Caballero OL, Zago MA, Colleoni GW. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 2008, 8:2. 2935785, 18237105.
31. Napoletano C, Bellati F, Tarquini E, Tomao F, Taurino F, Spagnoli G, Rughetti A, Muzii L, Nuti M, Benedetti Panici P. MAGE-a and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol 2008, 198:e91-e99.
32. Grau E, Oltra S, Martinez F, Orellana C, Canete A, Fernandez JM, Hernandez-Marti M, Castel V. MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors. J Cancer Res Clin Oncol 2009, 135:523-531. 10.1007/s00432-008-0484-1, 18820946.
33. Bandic D, Juretic A, Sarcevic B, Separovic V, Kujundzic-Tiljak M, Hudolin T, Spagnoli GC, Covic D, Samija M. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J 2006, 47:32-41. 2080373, 16489695.
34. Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, et al. MAGE-a, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 2007, 67:9954-9962. 10.1158/0008-5472.CAN-07-1478, 17942928.
35. Zhu X, Asa SL, Ezzat S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin Cancer Res 2008, 14:1984-1996. 10.1158/1078-0432.CCR-07-2003, 18381936.
36. Cilensek ZM, Yehiely F, Kular RK, Deiss LP. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther 2002, 1:380-387. 10.4161/cbt.1.4.12, 12432251.
37. Zhou JX, Li Y, Chen SX, Deng AM. Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma. J Exp Clin Cancer Res 2011, 30:2. 10.1186/1756-9966-30-2, 3023685, 21211023.
38. Perez D, Hauswirth F, Jager D, Metzger U, Samartzis EP, Went P, Jungbluth A. Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors. Int J Cancer 2011, 15:2947-2952.
39. Sienel W, Mecklenburg I, Dango S, Ehrhardt P, Kirschbaum A, Passlick B, Pantel K. Detection of MAGE-a transcripts in bone marrow is an independent prognostic factor in operable non-small-cell lung cancer. Clin Cancer Res 2007, 13:3840-3847. 10.1158/1078-0432.CCR-06-2507, 17606715.
40. Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Loning T, Janicke F, Pantel K. MAGE-a gene expression pattern in primary breast cancer. Cancer Res 2001, 61:6682-6687.
41. Taylor M, Bolton LM, Johnson P, Elliott T, Murray N. Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Res 2007, 9:R46. 10.1186/bcr1749, 2206722, 17650306.
42. Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang M, Xi S, Liu F, Marquez VE, Morgan RA, Schrump DS. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res 2011, 71:4192-4204. 10.1158/0008-5472.CAN-10-2442, 3116976, 21546573.
43. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000, 97:4760-4765. 10.1073/pnas.97.9.4760, 18306, 10781081.
44. Wang Y, Wu XJ, Zhao AL, Yuan YH, Chen YT, Jungbluth AA, Gnjatic S, Santiago D, Ritter G, Chen WF, et al. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun 2004, 4:11.
45. Hiroishi K, Eguchi J, Baba T, Shimazaki T, Ishii S, Hiraide A, Sakaki M, Doi H, Uozumi S, Omori R, et al. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol 2010, 45:451-458. 10.1007/s00535-009-0155-2, 19936602.
46. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res 2009, 15:2130-2139. 10.1158/1078-0432.CCR-08-2632, 19276258.
47. Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG. Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 2003, 9:3222-3234.
48. Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, Godelaine D. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 2000, 86:835-841. 10.1002/(SICI)1097-0215(20000615)86:6<835::AID-IJC12>3.0.CO;2-N, 10842198.
49. Jager D, Stockert E, Gure AO, Scanlan MJ, Karbach J, Jager E, Knuth A, Old LJ, Chen YT. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res 2001, 61:2055-2061.
50. Giger OT, Lacoste E, Honegger C, Padberg B, Moch H, Varga Z. Expression of the breast differentiation antigen NY-BR-1 in a phyllodes tumor of the vulva. Virchows Arch 2007, 450:471-474. 10.1007/s00428-007-0377-8, 17318573.
51. Seil I, Frei C, Sultmann H, Knauer SK, Engels K, Jager E, Zatloukal K, Pfreundschuh M, Knuth A, Tseng-Chen Y, et al. The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. Int J Cancer 2007, 120:2635-2642. 10.1002/ijc.22620, 17330232.
52. Jager D, Karbach J, Pauligk C, Seil I, Frei C, Chen YT, Old LJ, Knuth A, Jager E. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun 2005, 5:11.
53. Theurillat JP, Zurrer-Hardi U, Varga Z, Storz M, Probst-Hensch NM, Seifert B, Fehr MK, Fink D, Ferrone S, Pestalozzi B, et al. NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol Immunother 2007, 56:1723-1731. 10.1007/s00262-007-0316-1, 17410359.